Commentary on “It is time to share Alzheimer biomarker results in dementia with Lewy bodies”
Abstract Many people with dementia with Lewy bodies (DLB) have evidence of Alzheimer's disease (AD) co‐pathology, which can be assessed in vivo using biomarkers. In this issue, Armstrong and colleagues argue that it is now timely to disclose such AD biomarker results to people with DLB. They pr...
| Published in: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1002/dad2.70145 |